株式会社凜研究所
Tokyo, Japan · Founded 2016
- Headquarters
- Tokyo, Tokyo
- Founded
- 2016
- Website
- rinmab.co.jp
About
RIN Institute is a bio-venture established at the National Cancer Center Japan focused on R&D of medicines and diagnostic drugs based on monoclonal antibodies. Its lead program, a humanized anti-TMEM180 monoclonal antibody for treating several cancers including colorectal cancer, began a phase 1 trial at the National Cancer Center in January 2023. The company is also developing a humanized anti-insoluble fibrin antibody conjugate for the treatment of invasive tumors.
Summary
株式会社凜研究所 is a Biotech company based in Tokyo, Japan, founded in 2016.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/rinmab"><img src="https://indexed.vc/api/badge/company/rinmab" alt="株式会社凜研究所 on Indexed.vc" width="260" height="76" /></a>